Health charities Diabetes UK, the British Heart Foundation and the Juvenile Diabetes Research Foundation are funding the five year international study.
It is aimed to prevent high-risk 11-16 year olds developing heart and kidney disease.
Statins and ACA inhibitors have been shown to help reduce the risk of cardiovascular and kidney disease in adults with diabetes – but Cambridge University’s Adolescent Type I Diabetes Intervention Trial will be the first to focus on young people.
Researchers from the university’s Department of Paediatrics will coordinate with 11 other sites in the UK, Canada and Australia to find 500 adolescents with high protein levels in their urine, indicating risk of heart and kidney disease later in life.
They also want to find 400 subjects with lower protein levels at low or medium risk of developing diabetes-related conditions.
High risk groups will receive either statin and placebo, ACE inhibitor and placebo, both ACE inhibitor and statin, or placebo and placebo.